The production of antileukemic enzyme methionine γ-lyase (MGL) in distinctly related bacteria, Citrobacter freundii and in their recombinants expressing the Vitresocilla hemoglobin (VHb) has been studied. This study concerns the potential of Citrobacter freundii expressing the Vitreoscilla hemoglobin gene (vgb) for the methionine γ-liyase production. Methionine 
INTRODUCTION
Enzymes far exceed man-made catalysts in their reaction specificity, catalytic efficiency, and capacity to operate under mild conditions of temperature and hydrogen ion concentration. As drugs, enzymes have two important features that distinguish them from all other types of drugs. First, enzymes often bind and act on their targets with great affinity and specificity. Second, enzymes are catalytic and convert multiple target molecules to desired products. These two features make enzymes specific and potent drugs that can accomplish therapeutic biochemistry in the body that small molecules cannot. These characteristics have resulted in the development of many enzyme drugs for a wide range of disorders (1). L-Methionine γ-lyase (MGL; EC 4.4.1.11) is a pyridoxal 5'-phosphate (PLP)-dependent multifunctional enzyme which catalyzes α, γ-elimination and γ-replacement of L-methionine and its derivatives and also α, β-elimination and β-replacement of S-substituted L-cysteines (2-4). This activity was first found using dried cells of E. coli and Proteus vulgaris (4). MGL have been isolated, purified, and characterized from several microorganisms such as Pseudomonas putida, Clostridium sporogenes, Aeromonas sp., Citrobacter intermedius, Citrobacter freundii, Brevibacterium linens, Trichomonas vaginalis, . MGL has not been found in yeast and mammals (7, 10, 11) . Several practical applications of MGL have been reported. MGL has demonstrated antitumour efficacy in a number of methionine-dependent cancer cell lines including lung cancer, colon cancer, kidney cancer, brain cancer, prostate cancer, melanoma and fibrosarcoma (7). The antitumor efficacy of MGL, which is based on the greater L-methionine dependency of cancer cells for growth compared to normal cells has been investigated (3). Many human cancer cell lines and primary tumors have an absolute requirement for L-methionine, an essential amino acid (2). In vitro studies have demonstrated that several murine and human tumor cell lines need exogenous methionine to survive and proliferate (12). On the other hand, normal cells can utilize homocysteine to synthesis adequate levels of methionine and support a normal cell cycle. For these reasons; normal human cells are relatively resistant to exogenous L-methionine restriction (12). Numerous human cancer cell lines and primary tumors have an absolute requirement for L-methionine, an essential amino acid. On the other hand, normal human cells are relatively resistant to exogenous L-methionine restriction. Thus, depletion of L-methionine is effective for cancer therapy (13). Upon L-methionine depletion, L-methionine-dependent cancer cells are not able to divide and become arrested in the late-S/G2 phase of the cell cycle (2, 3, 12, 14) . Cell cycle arrested and death can be reversed by addition of exogenous methionine (12). On the other hand, normal human cells are relatively resistant to exogenous L-methionine restriction. Thus, depletion of L-methionine is effective for cancer therapy. The therapeutically utility of the enzyme for depleting L-methionine has been reported (2). The enzyme has been found to be an effective anti-tumor agent in vitro and in vivo and to be of potential value in the treatment of Parkinson's disease, arteriosclerosis, aging and obesity (9). Citrobacter freundii, Gram-negative, nonperforming rods belonging to the family Enterobacteriaceae and commonly found in soil, water, sewage, food, and the intestinal tracts of animal and human (15, 16) . http://bmbreports.org BMB reports freundii and their MK57 and MK79 harboring recombinants grown in LB medium for 24-96 h. Cells were grown a gyratory water-bath at 30°C in 150-ml volume flasks containing 50 ml culture medium. Each value is the average of at least three independent experiments. For clarity, no error bars are given, but they are mostly less than 10% of the respective data point. Each value is the average of at least three independent experiments. For clarity, no error bars are given, but they are mostly less than 10% of the respective data point.
In the aerobic bacterium Vitreoscilla, the synthesis of homodimeric hemoglobin (VHb), currently the only well known prokaryotic hemoglobin, can be induced under hypoxic conditions. The expression is maximally activated both in Vitreoscilla and E. coli under micro aerobic conditions, when the dissolved oxygen levels drops below 10% of air saturation. The vgb has been cloned into a variety of bacteria and eukaryotic organism mostly for the purpose of enhancing respiration, growth and productivity (17).
The aim of the present study was to determine the potential of VHb, protein known for its beneficiary effect on cell growth on metabolite production, on MGL production, an anticancer agent C. freundii. The presence of vgb/VHb may prove useful in this application.
RESULTS AND DISCUSSION
The production of MGL was studied in C. freundii and in their recombinants harboring the vgb. The effect of VHb on production of MGL by C. freundii was distinct. The strain of this bacterium, MK79, expressing VHb responded differently to carbon catabolite repression of the enzyme. The intracellular MGL level was determined cultures harvested at 96 h. Our preliminary studies showed that this compound was produced during the late (post-stationary) secondary phase of growth (Fig. 1b, 
